Compare KITT & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITT | QNRX |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 9.2M |
| IPO Year | N/A | 2023 |
| Metric | KITT | QNRX |
|---|---|---|
| Price | $1.09 | $4.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 232.6K | ★ 325.3K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $3.25 |
| 52 Week High | $6.93 | $41.80 |
| Indicator | KITT | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.03 | 51.01 |
| Support Level | $1.05 | $4.25 |
| Resistance Level | $1.23 | $5.11 |
| Average True Range (ATR) | 0.14 | 0.58 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 12.22 | 81.87 |
Nauticus Robotics Inc is a technology-driven company specializing in the development of fully electric autonomous robotic solutions for subsea applications. Its portfolio includes autonomous underwater vehicles (AUVs), electric robotic manipulators, a platform-agnostic robotic operating system, and related engineering, consulting and prototype services. The Company's solutions enable autonomous operations for both commercial and defense sectors, with alignment to offshore energy and national security interests. Its addressable markets include upstream, midstream and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research and subsea mining, with current focus on oil and gas operations and defense applications.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.